Literature DB >> 20421779

Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy.

Paul Ryan1, Sulaiman Nanji, Aaron Pollett, Malcolm Moore, Carol-Anne Moulton, Steven Gallinger, Maha Guindi.   

Abstract

The use of newer chemotherapeutic agents before resection of colorectal cancer liver metastases has been linked with parenchymal liver injury, in particular preoperative irinotecan and oxaliplatin with chemotherapy-associated steatohepatitis (CASH) and vascular parenchymal injury, respectively. We retrospectively assessed 334 cases from 2002 to 2007 and correlated pathologic findings with chemotherapy use and perioperative course. Features of fatty liver disease were graded according to established schemes, and several features of vascular injury, including sinusoidal dilation, nodular regenerative hyperplasia and parenchymal extinction lesions (PELs), were also scored semiquantitatively and a combined vascular injury (CVI) score was determined. Moderate and severe fatty injury was uncommon with steatohepatitis detected in 8 cases (2.4%), 7 of whom did not receive chemotherapy. Multivariate analysis showed steatosis greater than 33% and steatohepatitis were independently associated with Body Mass Index of 30 or more (P<0.001) but not chemotherapy. Vascular injuries were detected in 117 cases, were significantly associated with oxaliplatin, and the combined assessment of vascular features (a CVI score of 3 or more) was more strongly associated with oxaliplatin (P=0.0004) than any one feature in isolation. Perioperative outcome was not associated with parenchymal injury or preoperative chemotherapy. We conclude that although CASH is uncommon in this population vascular injury is frequently seen in resection specimens, but pathologic examination limited to sinusoidal dilation misses the majority of these. Semiquantitative measurement enables reproducible assessment of vascular injuries, allows comparison between studies, and may help inform future treatment decisions in patients with limited hepatic reserve.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20421779     DOI: 10.1097/PAS.0b013e3181dc242c

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  24 in total

Review 1.  Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension.

Authors:  Marek Hartleb; Krzysztof Gutkowski; Piotr Milkiewicz
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

2.  Sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy.

Authors:  An Na Seo; Haeryoung Kim
Journal:  Clin Mol Hepatol       Date:  2014-03

3.  Chemotherapy-Associated Liver Injuries: Unmet Needs and New Insights for Surgical Oncologists.

Authors:  Luca Vigano; Martina Sollini; Francesca Ieva; Francesco Fiz; Guido Torzilli
Journal:  Ann Surg Oncol       Date:  2021-04-30       Impact factor: 5.344

4.  Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin.

Authors:  Si Xuan Koo; Sock Hoai Chan; Joanne Ngeow
Journal:  BMJ Case Rep       Date:  2016-01-04

5.  Sinusoidal obstruction syndrome compromises liver regeneration in patients undergoing two-stage hepatectomy with portal vein embolization.

Authors:  Masato Narita; Elie Oussoultzoglou; Marie-Pierre Chenard; Edoardo Rosso; Selenia Casnedi; Patrick Pessaux; Philippe Bachellier; Daniel Jaeck
Journal:  Surg Today       Date:  2010-12-30       Impact factor: 2.549

Review 6.  Curative strategies for liver metastases from colorectal cancer: a review.

Authors:  Nicholas Zdenkowski; Stanley Chen; Andre van der Westhuizen; Stephen Ackland
Journal:  Oncologist       Date:  2012-01-10

7.  Magnetic resonance imaging flowmetry demonstrates portal vein dilatation subsequent to oxaliplatin therapy in patients with colorectal liver metastasis.

Authors:  Jozef Urdzik; Tomas Bjerner; Alkwin Wanders; Frans Duraj; Ulf Haglund; Agneta Norén
Journal:  HPB (Oxford)       Date:  2012-08-20       Impact factor: 3.647

8.  Prospective diagnostic test accuracy comparison of computed tomography during arterial portography and Primovist magnetic resonance imaging in the pre-operative assessment of colorectal cancer liver metastases.

Authors:  Jai S Bagia; Alan Chai; Roger Chou; Christopher Chu; John Rouse; Elizabeth Sinclair; Leon Vonthethoff; Armando Teixeira-Pinto
Journal:  HPB (Oxford)       Date:  2015-08-10       Impact factor: 3.647

9.  Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS study.

Authors:  Jing Qi; Yuman Fong; Leonard Saltz; Michael I D'Angelica; Nancy E Kemeny; Mithat Gonen; Jinru Shia; Amita Shukla-Dave; William R Jarnagin; William M Jarnagin; Richard K G Do; Lawrence H Schwartz; Jason A Koutcher; Kristen L Zakian
Journal:  NMR Biomed       Date:  2012-09-07       Impact factor: 4.044

10.  Hepatic histopathology and postoperative outcome after preoperative chemotherapy for Chinese patients with colorectal liver metastases.

Authors:  Qi-Ying Lu; Ai-Lian Zhao; Wei Deng; Zhong-Wu Li; Lin Shen
Journal:  World J Gastrointest Surg       Date:  2013-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.